Clinical Trials Logo

Cardiac Amyloidosis clinical trials

View clinical trials related to Cardiac Amyloidosis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03333551 Terminated - Cardiac Amyloidosis Clinical Trials

Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy

Start date: October 1, 2020
Phase: Phase 4
Study type: Interventional

This is a pilot study designed to assess for relative change in cardiac 18F Florbetapir uptake in patients with AL cardiac amyloidosis after appropriate chemotherapy.

NCT ID: NCT03328338 Terminated - Cardiac Amyloidosis Clinical Trials

Mitochondrial Function in Transthyretin Amyloidosis

MIT-Amylose
Start date: July 17, 2018
Phase:
Study type: Observational

Hereditary (familial) amyloidosis arising from the misfolding of a mutated or variant transthyretin, is the most frequent form of amyloid cardiomyopathy in the Caribbean basin. Affected organs invariably harbor extracellular amyloid deposits in the myocardium. Circulating or pre-fibrillar amyloidogenic proteins are implicated in the disruption of cell function. The investigators aim is to demonstrate that transthyretin mediated amyloid disease alter the mitochondrial function of cardiac cells.

NCT ID: NCT03232632 Terminated - Cardiac Amyloidosis Clinical Trials

Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.

AMYLCAR
Start date: March 15, 2017
Phase: Early Phase 1
Study type: Interventional

To estimate distribution's parameters of 18F-Flutemetamol (Vizamyl®) fixation on myocardium for patients with amyloid cardiac injuries.

NCT ID: NCT03040427 Terminated - Cardiac Amyloidosis Clinical Trials

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

Start date: January 2017
Phase: Phase 4
Study type: Interventional

The investigators postulate that F-18 florbetapir will show improved detection of cardiac amyloidosis over conventional non-invasive imaging techniques, particularly in early disease.

NCT ID: NCT01683825 Terminated - Cardiac Amyloidosis Clinical Trials

Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography

Start date: March 23, 2013
Phase: Phase 4
Study type: Interventional

The primary aim of this pilot study is to determine whether amyloid deposits in the heart can be measured non-invasively by F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET) in 30 individuals with documented cardiac amyloidosis. We will also enroll 15 individuals without cardiac amyloidosis to undergo the F-18 florbetapir imaging as a control group. The primary hypothesis of this study is that a specific amyloid binding radiotracer will bind to the myocardial amyloid deposits and help quantify cardiac amyloid burden. A secondary aim of this study is to determine reproducibility of F-18 florbetapir imaging of the myocardium.